Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | FSHR | P23945 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9058303 | 0.89 | FSHR (0.34) | ALDH1A1FSHRTSHR | |
| SCHEMBL2391024 | 0.87 | ALDH1A1 (0.43) | ALDH1A1NPSR1FSHRTSHR | |
| SCHEMBL2390544 | 0.87 | ALDH1A1 (0.43) | ALDH1A1NPSR1FSHRTSHR | |
| SCHEMBL8988951 | 0.86 | ALDH1A1 (0.44) | ALDH1A1NPSR1RIPK1FFAR4 | |
| SCHEMBL9057079 | 0.85 | TSHR (0.41) | FSHRTSHR | |
| SCHEMBL9055088 | 0.84 | TSHR (0.40) | TSHR | |
| SCHEMBL9057067 | 0.84 | FSHR (0.37) | ALDH1A1FSHRTSHR | |
| SCHEMBL9056297 | 0.82 | FSHR (0.35) | FSHRTSHR | |
| SCHEMBL14233580 | 0.79 | TSHR (0.39) | FSHRTSHR | |
| SCHEMBL13619993 | 0.79 | RIPK1 (0.38) | ALDH1A1NPSR1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188279-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | ALDH1A1 466/4885NPSR1 1233/4885FSHR 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.